{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-056363","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.684813+00:00","generated_at":"2026-06-18T16:54:49.183524+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inovio Q4 net loss $54.5M; VGX-3100 Phase 3 trial fails primary endpoint in biomarker group","bullets":["Net loss of $54.5M ($0.22 per share) for Q4 2022; full year net loss $279.8M ($1.17 per share).","Cash and short-term investments $253M as of Dec 31, 2022; cash runway projected into Q1 2025.","REVEAL2 Phase 3 trial of VGX-3100 did not meet primary endpoint in biomarker-selected population (p=0.115); but achieved statistical significance in all-participants population (p=0.001).","Positive Phase 1/2 data for INO-3107 in RRP: median decrease of 3 surgical interventions; 91% of patients saw reduction.","Positive Phase 1b data for INO-4201 as Ebola booster: 100% of treated participants boosted humoral responses."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-056363","json":"https://secwatch.observer/filing/0001193125-23-056363.json","markdown":"https://secwatch.observer/filing/0001193125-23-056363.md","text":"https://secwatch.observer/filing/0001193125-23-056363.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000119312523056363/0001193125-23-056363-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000119312523056363/d378213d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T16:54:49.183524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0cde91145cb2a3abff5edeef80d83753dfb5f019","claim":"INOVIO PHARMACEUTICALS, INC. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On March 1, 2023, Inovio Pharmaceuticals, Inc. (the \" Company \") issued a press release announcing its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1055726/000119312523056363/0001193125-23-056363-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}